|View printer-friendly version|
|BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS|
The trial is expected to enroll approximately 200 patients and will be conducted at six leading ALS clinical sites in the U.S. The primary outcome measure will be the ALSFR-S score responder analysis. The patient population will be optimized to include the pre-specified subgroups who demonstrated superior outcomes in the NurOwn® Phase 2 ALS clinical trial. Top-line data are expected in 2019. For more information, refer to www.clinicaltrials.gov , using the NCT identifier NCT03280056.
"NurOwn® is a highly innovative and advanced stem cell therapy now being studied in a phase 3 trial in ALS. The support of this trial by the
This trial is supported by a
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-enrolls-first-patients-in-phase-3-trial-of-nurown-in-als-300536911.html